Beta Blockers reduce Mortality in Heart Failure Patients with CKD, claims study
Current national guidelines recommend that clinicians treat patients with heart failure and left ventricular systolic dysfunction with β-adrenergic receptor blockers (β-blockers), based on robust evidence from several randomized clinical trials showing a reduction in mortality and morbidity. More than two-thirds of patients with heart failure also have chronic kidney disease (CKD), which independently increases the risk of adverse cardiovascular events and death.
According to a new study published in the American Journal of Kidney Diseases, β-blockers have been associated with a lower rate of mortality among incident hemodialysis patients with Heart failure.
To date,β-blockers are recommended for heart failure (HF) patients but their benefit in the dialysis population is uncertain. β-blockers are heterogeneous including concerning their removal by hemodialysis.
With this in view, researchers sought to evaluate whether β-blocker use and their dialyzability characteristics were associated with early mortality among chronic kidney disease (CKD) patients with HF who transitioned to dialysis.
The research team made undertook a Retrospective cohort study with participants as adult patients with CKD (age ≥ 18 years) and HF who initiated either hemodialysis or peritoneal dialysis during 1/1/2007-6/30/2016 within an integrated health system.
Patients were considered treated with β-blockers if they had a quantity of drug dispensed covering the dialysis transition date.
The primary outcome that was evaluated was all-cause mortality within 6 months and 1 year, or hospitalization within 6 months after transitioning to maintenance dialysis.
On data analysis, the following facts emerged.
- A total of 3,503 patients were included in the study.
- There were 2,115 (60.4%) patients on β-blockers at transition.
- Compared to non-users, the hazard ratio for all-cause mortality within 6 months was 0.79 (95% CI: 0.65-0.94) among users of any β-blocker, and 0.68 (95% CI: 0.53-0.88) among users of metoprolol at transition.
- There were no observed differences in all-cause or cardiovascular-related hospitalization.
For the full article click on the link: https://doi.org/10.1053/j.ajkd.2020.07.023
Primary source: American Journal of Kidney Diseases
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.